Anna Rosell Novel Graduated in Biology (2001) and PhD in Medicine (2005), both at Universitat Autònoma de Barcelona. My scientific education and expertise has been focused in the translational study of stroke disease and therapies. I obtained a Miguel Servet research position in 2010 from the Spanish National Institute of Health and Research Agency (Instituto Carlos III), and since February 2016 I hold a Tenure position at VHIR as Principal Investigator and Head of the Neurovascular Research Laboratory. Institutions of which they are part Head of group Neurovascular Diseases Vall Hebron Institut de Recerca Email Anna Rosell Novel Email Institutions of which they are part Head of group Neurovascular Diseases Vall Hebron Institut de Recerca Graduated in Biology (2001) and PhD in Medicine (2005), both at Universitat Autònoma de Barcelona. My scientific education and expertise has been focused in the translational study of stroke disease and therapies. I obtained a Miguel Servet research position in 2010 from the Spanish National Institute of Health and Research Agency (Instituto Carlos III), and since February 2016 I hold a Tenure position at VHIR as Principal Investigator and Head of the Neurovascular Research Laboratory.
As a PhD student at Vall d’Hebron Research Institute (VHIR) I was trained in the biomarkers field and clinical stroke studies, which gave me a solid understanding of the disease from a clinical perspective. After I moved to the United States for a Postdoctoral position at the Massachusetts General Hospital in a world-leading laboratory recognized for their experimental studies in cerebral ischemia (Neuroprotection Research Laboratory-MGH), which offered me the opportunity to extend my experience at a more basic and experimental level. I obtained a Miguel Servet position in 2010 from the Spanish National Institute of Health and Research Agency (Instituto Carlos III), and since February 2016 I hold a Tenure position at VHIR as Principal Investigator and since 2017 I am the head of the Neurovascular Research Laboratory. The main focus of my research is the search of new therapies for stroke patients based on neurorepair strategies with specific emphasis on the role of angio-vasculogenesis using nanomedicine and cell-therapy approaches for regenerative medicine. This has allowed me to obtain independent funding as PI from national agencies, Euronanomed program and private foundations, to supervise and guide PhD Students, Post-doctoral researchers, and establish national and International collaborations with other PIs in the neuroscience, regenerative medicine and nanotechnology fields. I do have the research accreditation of Associate Professor from AQU. My group has a distinction of Consolidated Research Group by AGAUR (2017SGR 1427) and belongs to the Spanish Cooperative Network for Research in Cerebrovascular Diseases (RICORS-2022).
Projects Malalties neurovasculars IP: Anna Rosell Novel Collaborators: Mercedes Arrúe Gonzalo, Joan Montaner Villalonga, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Antonio Palasi Franco, Jesús Pizarro Gonzálvez, Miguel García Gabilondo, Nicolas Garcia Rodriguez Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 00656 Duration: 01/01/2022 - 30/06/2025 Tratamientos endovasculares de neuroprotección y neuroreparación en la recuperación del ictus. IP: Anna Rosell Novel Collaborators: Anna Penalba Morenilla, Miguel García Gabilondo Funding agency: Instituto de Salud Carlos III Funding: 141570 Reference: PI22/01055 Duration: 01/01/2023 - 31/12/2025 Endothelial progenitor cells labelled with superparamagnetic iron oxide micro and nanoparticles in cerebrovascular disorders, process for their preparation and uses thereof. IP: Anna Rosell Novel Collaborators: Miguel García Gabilondo Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 71734.81 Reference: SLT017/20/000197 Duration: 01/07/2021 - 31/12/2023 RICORS-ICTUS IP: Anna Rosell Novel Collaborators: Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Jesús Pizarro Gonzálvez Funding agency: Instituto de Salud Carlos III Funding: 250214.8 Reference: RD21/0006/0007 Duration: 01/01/2022 - 31/12/2024 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 … Next page › Last page »
